Back to top
more

atai Life Sciences (ATAI)

(Delayed Data from NSDQ)

$2.05 USD

2.05
1,176,353

-0.08 (-3.76%)

Updated May 3, 2024 04:00 PM ET

After-Market: $2.05 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Universal Health (UHS) Stock Now

by Zacks Equity Research

Universal Health (UHS) benefits from improving patient volumes, sound segmental performance and a solid capital position.

Tenet Healthcare (THC) & Oracle Unite to Improve Efficiency

by Zacks Equity Research

Tenet Healthcare (THC) collaborates with Oracle Cloud HCM to improve and automate human resources and payroll processes.

Here's Why Investors Should Retain Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna's (CI) strong Evernorth and Cigna Healthcare segments, growing medical membership and a positive 2023 outlook poise it well for growth.

Here's Why Investors are Buying HCA Healthcare (HCA) Stock Now

by Zacks Equity Research

With seniors resuming delayed elective procedures, demand for services provided by HCA Healthcare (HCA) is likely to rise.

The Joint (JYNT) Q2 Earnings Miss Estimates, 2023 View Down

by Zacks Equity Research

The Joint (JYNT) expects to open 100-120 franchised clinics in 2023 compared with 121 opened last year.

Encompass Health (EHC) Opens JV Hospital With Piedmont in Georgia

by Zacks Equity Research

The Rehabilitation Hospital of Columbus is Encompass Health's (EHC) sixth location in the state of Georgia.

Brookdale's (BKD) August 2023 Occupancy & Move-in Volumes Rise

by Zacks Equity Research

Brookdale (BKD) has witnessed 22 straight months of year-over-year increases in the weighted average occupancy level.

Molina Healthcare (MOH) Closes $150M My Choice Wisconsin Buyout

by Zacks Equity Research

Molina Healthcare (MOH) completes the My Choice Wisconsin acquisition ahead of the updated scheduled time.

Here's Why Investors are Retaining Elevance (ELV) Stock Now

by Zacks Equity Research

Elevance's (ELV) focus on expanding the capabilities of the Carelon platform is likely to position the company for long-term growth.

atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why You Should Retain UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Growth in membership, expanding government business, strategic acquisitions and improving operating margin poise UnitedHealth Group (UNH) well for growth.

Cigna's (CI) Unit Brings New Plan for Globally Mobile Seniors

by Zacks Equity Research

The new product from Cigna's (CI) Cigna Healthcare unit is likely to face significant demand in the global market.

HCA Healthcare (HCA) & Google Cloud Unite to Improve Efficiency

by Zacks Equity Research

HCA Healthcare (HCA) partners with Google Cloud to improve and automate workflows.

Why Investors Are Snapping Up Tenet Healthcare (THC) Stock Now

by Zacks Equity Research

Tenet Healthcare (THC) patient volumes are likely to remain high as seniors resume elective procedures, which were delayed due to pandemic-related constraints.

Cigna (CI) Unit to Offer ACA Plans in 350 Counties in 2024

by Zacks Equity Research

Cigna (CI) plans to expand coverage in 15 counties in North Carolina and reach an additional 200,000 ACA Marketplace clients.

Is UnitedHealth (UNH) a Good Dividend Stock Choice for You?

by Zacks Equity Research

UnitedHealth's (UNH) strong balance sheet and cash-generating ability support its endeavors to return shareholders' funds.

Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)

by Zacks Equity Research

atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Why Prudent Investors Are Snapping Up Ensign (ENSG) Stock Now

by Zacks Equity Research

Ensign (ENSG) expects to witness strong acquisition opportunities in the fall of this year.

Here's Why Encompass Health (EHC) Stock is a Strong Buy Now

by Zacks Equity Research

Encompass Health's (EHC) focus on boosting the number of licensed beds and hospitals will likely enhance market density and build scale.

ATI Physical Therapy, Inc. (ATIP) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of 0% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Misses Q4 Earnings Estimates

by Zacks Equity Research

RadNet (RDNT) delivered earnings and revenue surprises of -42.11% and 11.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 14.43% and 0.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)

by Zacks Equity Research

atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage

by Zacks Equity Research

ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.